SCHEMBL4110308

SCHEMBL4110308

COC(=O)c1ccc(NC(=O)Nc2ccc(C(=O)OC(C)C)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.68
ALDH1A1 P00352 4/20 0.68
NPC1 O15118 10/20 0.66
MEN1 O00255 9/20 0.66
KMT2A Q03164 9/20 0.66
RAB9A P51151 9/20 0.66
HTT P42858 3/20 0.66
KDM4E B2RXH2 3/20 0.66
MAPK1 P28482 2/20 0.66
SMN1; SMN2 Q16637 4/20 0.65
LMNA P02545 2/20 0.65
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA7 P43166 1/20 0.56
CA9 Q16790 1/20 0.56
CA14 Q9ULX7 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4113137 0.89 MAPT (0.74) MAPTALDH1A1NPC1MEN1KMT2A
SCHEMBL4117961 0.89 MAPT (0.71) MAPTALDH1A1NPC1MEN1KMT2A
SCHEMBL4122707 0.89 NPC1 (0.63) MAPTALDH1A1NPC1MEN1KMT2A
SCHEMBL13800480 0.88 CA1 (0.70) MAPTALDH1A1NPC1MEN1KMT2A
SCHEMBL4112874 0.87 MAPT (0.71) MAPTALDH1A1NPC1MEN1KMT2A
SCHEMBL4127725 0.86 RAB9A (0.60) MAPTALDH1A1NPC1MEN1KMT2A
SCHEMBL4104717 0.83 MAPT (0.64) MAPTALDH1A1NPC1MEN1KMT2A
SCHEMBL28511768 0.82 MAPT (0.71) MAPTALDH1A1NPC1MEN1KMT2A
SCHEMBL4105717 0.82 ALDH1A1 (0.56) MAPTALDH1A1NPC1MEN1KMT2A
SCHEMBL4112196 0.82 TP53 (0.68) MAPTALDH1A1NPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MAPT 1654/4885ALDH1A1 994/4885NPC1 927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.